Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Ursodeoxycholic Acid Attenuates B Cell Susceptibility to SARS-CoV-2 Spike Protein by Interfering Its Binding to ACE2

  • So-Jeong Park (Department of Integrative Bioscience and Biotechnology, Sejong University) ;
  • Eun-Yi Moon (Department of Integrative Bioscience and Biotechnology, Sejong University)
  • Received : 2025.08.05
  • Accepted : 2025.08.27
  • Published : 2025.11.01
Download PDF
⟨ Previous Next ⟩

Abstract

B cells are essential for the defense against various infectious agents including severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) causing coronavirus disease 2019 (COVID-19). COVID-19 is caused by interaction of the spike protein (SP) with the receptor-binding domain (RBD) and its receptor, angiotensin converting enzyme 2 (ACE2). Bisphenol A (BPA), a plasticizer and endocrine-disrupting chemical, can enter the human body through several exposure routes. Previously, we reported human B cell death by BPA treatment via autophagy induction. Here, we investigated whether the exposure to BPA affects B cell susceptibility to SP of COVID-19 and how to interfere the interaction of SP and ACE2. We observed an increase in ACE2 gene expression in human B cells by BPA treatment and more SP binding in BPA-treated B cells. Our data also showed more B cell death accompanying increased autophagic puncta count and lysosomal intracellular activity by co-treatment with BPA and SP compared to those in BPA treatment alone. Ursodeoxycholic acid (UDCA) reduced SP binding in B cells in BPA-exposed B cells. UDCA treatment also inhibited B cell death and lysosomal enzyme activity which were enhanced by co-treatment of BPA and SP. Taken together, results demonstrate that BPA-exposed B cells are more susceptible to COVID-19. It also suggests that UDCA could be protective to SP-responding B cells exposed to BPA.

Keywords

Acknowledgement

We sincerely thank Dae Heum Yun for his technical assistance in our experiment. This research was supported by the Basic Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (grant number RS-2023-00244570).

References

  1. Abdelkader, N. F., Safar, M. M. and Salem, H. A. (2016) Ursodeoxycholic acid ameliorates apoptotic cascade in the rotenone model of Parkinson's disease: modulation of mitochondrial perturbations. Mol. Neurobiol. 53, 810-817.
  2. Carino, A., Moraca, F., Fiorillo, B., Marchiano, S., Sepe, V., Biagioli, M., Finamore, C., Bozza, S., Francisci, D., Distrutti, E., Catalanotti, B., Zampella, A. and Fiorucci, S. (2020) Hijacking SARS-CoV-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on the receptor binding domain. Front. Chem. 8, 572885.
  3. Costello, R. E., Waller, K. M. J., Smith, R., Mells, G. F., Wong, A. Y. S., Schultze, A., Mahalingasivam, V., Herrett, E., Zheng, B., Lin, L. Y., MacKenna, B., Mehrkar, A., Bacon, S. C. J., Goldacre, B., Tomlinson, L. A., Tazare, J. and Rentsch, C. T.; OpenSAFELY collaborative; LH&W NCS (or CONVALESCENCE) Collaborative (2024) Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform. Commun. Med. (Lond.) 4, 238.
  4. DiLillo, D. J., Horikawa, M. and Tedder, T. F. (2011) B-lymphocyte effector functions in health and disease. Immunol. Res. 49, 281-292.
  5. Eki̇ci̇, M., Ozkaraca, M. and Ataseven, H. (2025) Ursodeoxycholic acid ameliorates paclitaxel-induced hepatic injury in rats: evaluation of oxidative and DNA damage, apoptosis and autophagy. Acta Vet. Hung. 73, 86-96.
  6. Geahlen, R. L. (2014) Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol. Sci. 35, 414-422.
  7. Hagey, L. R., Crombie, D. L., Espinosa, E., Carey, M. C., Igimi, H. and Hofmann, A. F. (1993) Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores. J. Lipid Res. 34, 1911-1917.
  8. Halajian, E. A., LeBlanc, E. V., Gee, K. and Colpitts, C. C. (2022) Activation of TLR4 by viral glycoproteins: a double-edged sword? Front. Microbiol. 13, 1007081.
  9. Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Muller, M. A., Drosten, C. and Pohlmann, S. (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271-280.e8.
  10. Itakura, E. and Mizushima, N. (2010) Characterization of autophagosome formation site by a hierarchical analysis of mammalian Atg proteins. Autophagy 6, 764-776.
  11. Jang, J. W., Lee, J. W., Yoon, Y. D., Kang, J. S. and Moon, E. Y. (2020) Bisphenol A and its substitutes regulate human B cell survival via Nrf2 expression. Environ. Pollut. 259, 113907.
  12. Kalampokis, I., Yoshizaki, A. and Tedder, T. F. (2013) IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res. Ther. 15 Suppl 1, S1.
  13. Kim, E. K., Cho, J. H., Kim, E. and Kim, Y. J. (2017) Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth. PLoS One 12, e0181183.
  14. Lapenna, D., Ciofani, G., Festi, D., Neri, M., Pierdomenico, S. D., Giamberardino, M. A. and Cuccurullo, F. (2002) Antioxidant properties of ursodeoxycholic acid. Biochem. Pharmacol. 64, 1661-1667.
  15. Lee, H., Kim, M. G., Yeom, S. W., Noh, S. J., Jeong, C. Y., Kim, M. J., Kang, M. G., Ko, J. H., Park, S. C., Kweon, H. T., Sim, S. I., Lee, H., You, Y. S. and Kim, J. S. (2024) Association between ursodeoxycholic acid and clinical outcomes in patients with COVID-19 infection: population-based cohort study. JMIR Public Health Surveill. 10, e59274.
  16. Lee, J. W., Lee, S. J., Gye, M. C. and Moon, E. Y. (2019) Genotoxicity and glucose tolerance induction by acetyltriethylcitrate, substitute plasticizer compared to di(2-ethylhexyl)phthalate. Sci. Rep. 9, 12237.
  17. Li, F., Berardi, M., Li, W., Farzan, M., Dormitzer, P. R. and Harrison, S. C. (2006) Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain. J. Virol. 80, 6794-6800.
  18. Lukivskaya, O., Zavodnik, L., Knas, M. and Buko, V. (2006) Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. Adv. Med. Sci. 51, 54-59.
  19. Mahapatra, K. K., Mishra, S. R., Behera, B. P., Patil, S., Gewirtz, D. A. and Bhutia, S. K. (2021) The lysosome as an imperative regulator of autophagy and cell death. Cell. Mol. Life Sci. 78, 7435-7449.
  20. Marino, G., Niso-Santano, M., Baehrecke, E. H. and Kroemer, G. (2014) Self-consumption: the interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell. Biol. 15, 81-94.
  21. Masters-Waage, T. C., Jha, N. and Reb, J. (2020) COVID-19, coronavirus, Wuhan virus, or China virus? Understanding how to "do no harm" when naming an infectious disease. Front. Psychol. 11, 561270.
  22. Miyaguchi, S. and Mori, M. (2005) Ursodeoxycholic acid (UDCA) suppresses liver interleukin 2 mRNA in the cholangitis model. Hepatogastroenterology 52, 596-602.
  23. Mroz, M. S. and Harvey, B. J. (2019) Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells. Steroids 151, 108461.
  24. Mustajab, T., Kwamboka, M. S., Khan, I., Song, D., Lee, S., Han, K. R., Han, Y., Kim, J. and Chwae, Y. J. (2025) Immunologic responses to an extracellular vesicle-based vaccine expressing the full suite of SARS-CoV-2 structural proteins. Vaccine 61, 127407.
  25. Niu, F., Li, H., Xu, X., Sun, L., Gan, N. and Wang, A. (2020) Ursodeoxycholic acid protects against lung injury induced by fat embolism syndrome. J. Cell. Mol. Med. 24, 14626-14632.
  26. Niu, F., Xu, X., Zhang, R., Sun, L., Gan, N. and Wang, A. (2019) Ursodeoxycholic acid stimulates alveolar fluid clearance in LPS-induced pulmonary edema via ALX/cAMP/PI3K pathway. J. Cell. Physiol. 234, 20057-20065.
  27. Park, S. J., Jang, J. W. and Moon, E. Y. (2023) Bisphenol A-induced autophagy ameliorates human B cell death through Nrf2-mediated regulation of Atg7 and Beclin1 expression by Syk activation. Ecotoxicol. Environ. Saf. 260, 115061.
  28. Paumgartner, G. and Beuers, U. (2002) Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36, 525-531.
  29. Rodal Canales, F. J., Perez-Campos Mayoral, L., Hernandez-Huerta, M. T., Sanchez Navarro, L. M., Matias-Cervantes, C. A., Martinez Cruz, M., Cruz Parada, E., Zenteno, E., Ramos-Martinez, E. G., Perez-Campos Mayoral, E., Romero Diaz, C. and Perez-Campos, E. (2021) Interaction of Spike protein and lipid membrane of SARS-CoV-2 with Ursodeoxycholic acid, an in-silico analysis. Sci. Rep. 11, 22288.
  30. Shi, Q. Y., Kong, B. H., Ma, K. D., Zhang, X. L. and Jiang, S. (2003) Effects of ursodeoxycholic acid on the liver plasma membrane fluidity, hepatic glutathione concentration, hepatic estrogen receptors and progesterone receptors in pregnant rats with ethinylestradiol and progesterone induced intrahepatic cholestasis. Zhonghua Fu Chan Ke Za Zhi 38, 680-682.
  31. Song, X., Hu, W., Yu, H., Zhao, L., Zhao, Y., Zhao, X., Xue, H. H. and Zhao, Y. (2023) Little to no expression of angiotensin-converting enzyme-2 on most human peripheral blood immune cells but highly expressed on tissue macrophages. Cytometry A 103, 136-145.
  32. Tao, L., Qiu, Y., Fu, X., Lin, R., Lei, C., Wang, J. and Lei, B. (2016) Angiotensin-converting enzyme 2 activator diminazene aceturate prevents lipopolysaccharide-induced inflammation by inhibiting MAPK and NF-kappaB pathways in human retinal pigment epithelium. J. Neuroinflammation 13, 35.
  33. Thuy, P. X., Bao, T. D. D. and Moon, E. Y. (2022) Ursodeoxycholic acid ameliorates cell migration retarded by the SARS-CoV-2 spike protein in BEAS-2B human bronchial epithelial cells. Biomed. Pharmacother. 150, 113021.
  34. Willart, M. A., van Nimwegen, M., Grefhorst, A., Hammad, H., Moons, L., Hoogsteden, H. C., Lambrecht, B. N. and Kleinjan, A. (2012) Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor. Allergy 67, 1501-1510.
  35. Wu, M., Lao, Y., Xu, N., Wang, X., Tan, H., Fu, W., Lin, Z. and Xu, H. (2015) Guttiferone K induces autophagy and sensitizes cancer cells to nutrient stress-induced cell death. Phytomedicine 22, 902-910.
  36. Wu, P., Zhao, J., Guo, Y., Yu, Y., Wu, X. and Xiao, H. (2020) Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK. Biochem. Biophys. Res. Commun. 529, 834-838.
  37. Xiao, X. and Dimitrov, D. S. (2004) The SARS-CoV S glycoprotein. Cell. Mol. Life Sci. 61, 2428-2430.
  38. Yang, Z. and Klionsky, D. J. (2010) Mammalian autophagy: core molecular machinery and signaling regulation. Curr. Opin. Cell Biol. 22, 124-131.
  39. Yao, C. W., Kang, K. A., Piao, M. J., Ryu, Y. S., Fernando, P., Oh, M. C., Park, J. E., Shilnikova, K., Na, S. Y., Jeong, S. U., Boo, S. J. and Hyun, J. W. (2017) Reduced autophagy in 5-fluorouracil resistant colon cancer cells. Biomol. Ther. (Seoul) 25, 315-320.
  40. Ye, H. L., Zhang, J. W., Chen, X. Z., Wu, P. B., Chen, L. and Zhang, G. (2020) Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy. Life Sci. 242, 117175.
  41. Yoshino, S., Yamaki, K., Yanagisawa, R., Takano, H., Hayashi, H. and Mori, Y. (2003) Effects of bisphenol A on antigen-specific antibody production, proliferative responses of lymphoid cells, and TH1 and TH2 immune responses in mice. Br. J. Pharmacol. 138, 1271-1276.
  42. Youinou, P., Taher, T. E., Pers, J. O., Mageed, R. A. and Renaudineau, Y. (2009) B lymphocyte cytokines and rheumatic autoimmune disease. Arthritis Rheum. 60, 1873-1880.
  43. Yu, L., Chen, Y. and Tooze, S. A. (2018) Autophagy pathway: cellular and molecular mechanisms. Autophagy 14, 207-215.
  44. Yurino, H., Ishikawa, S., Sato, T., Akadegawa, K., Ito, T., Ueha, S., Inadera, H. and Matsushima, K. (2004) Endocrine disruptors (environmental estrogens) enhance autoantibody production by B1 cells. Toxicol. Sci. 81, 139-147.
  45. Zahra, A., Sisu, C., Silva, E., De Aguiar Greca, S. C., Randeva, H. S., Chatha, K., Kyrou, I. and Karteris, E. (2020) Is there a link between bisphenol A (BPA), a key endocrine disruptor, and the risk for SARS-CoV-2 infection and severe COVID-19? J. Clin. Med. 9, pages.
  46. Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. D., Liu, M. Q., Chen, Y., Shen, X. R., Wang, X., Zheng, X. S., Zhao, K., Chen, Q. J., Deng, F., Liu, L. L., Yan, B., Zhan, F. X., Wang, Y. Y., Xiao, G. F. and Shi, Z. L. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273.
  47. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., Tan, W., China Novel Coronavirus, I. and Research, T. (2020) A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727-733.